HK1112059A1 - Methods and products for evaluating an immune response to a therapeutic protein - Google Patents

Methods and products for evaluating an immune response to a therapeutic protein

Info

Publication number
HK1112059A1
HK1112059A1 HK08107142.4A HK08107142A HK1112059A1 HK 1112059 A1 HK1112059 A1 HK 1112059A1 HK 08107142 A HK08107142 A HK 08107142A HK 1112059 A1 HK1112059 A1 HK 1112059A1
Authority
HK
Hong Kong
Prior art keywords
evaluating
products
methods
immune response
therapeutic protein
Prior art date
Application number
HK08107142.4A
Other languages
English (en)
Chinese (zh)
Inventor
Meena Subramanyam
Lakshmi Amaravadi
Eric Wakshull
Frances Lynn
Michael Panzara
Robin Mcdaid Barbour
Julie Elizabeth Taylor
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37023063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1112059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HK1112059A1 publication Critical patent/HK1112059A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
HK08107142.4A 2005-04-04 2008-06-27 Methods and products for evaluating an immune response to a therapeutic protein HK1112059A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66840405P 2005-04-04 2005-04-04
PCT/US2006/012493 WO2006107962A2 (en) 2005-04-04 2006-04-04 Methods and products for evaluating an immune response to a therapeutic protein

Publications (1)

Publication Number Publication Date
HK1112059A1 true HK1112059A1 (en) 2008-08-22

Family

ID=37023063

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08107142.4A HK1112059A1 (en) 2005-04-04 2008-06-27 Methods and products for evaluating an immune response to a therapeutic protein
HK18105030.1A HK1245884A1 (zh) 2005-04-04 2018-04-18 評價對治療性蛋白質的免疫應答的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18105030.1A HK1245884A1 (zh) 2005-04-04 2018-04-18 評價對治療性蛋白質的免疫應答的方法

Country Status (20)

Country Link
US (5) US8124350B2 (es)
EP (4) EP3796003A1 (es)
JP (3) JP2008537595A (es)
CN (1) CN101351710B (es)
AU (1) AU2006231511B2 (es)
CA (2) CA2603481C (es)
CY (2) CY1119412T1 (es)
DK (2) DK3264094T3 (es)
ES (3) ES2640295T3 (es)
HK (2) HK1112059A1 (es)
HR (2) HRP20171310T1 (es)
HU (2) HUE052412T2 (es)
IL (1) IL186431A (es)
LT (2) LT2645106T (es)
NZ (1) NZ562784A (es)
PL (2) PL3264094T3 (es)
PT (2) PT2645106T (es)
RS (2) RS56418B1 (es)
SI (2) SI3264094T1 (es)
WO (1) WO2006107962A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579583A (en) * 2002-02-25 2011-04-29 Elan Pharm Inc Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
JP2008537595A (ja) 2005-04-04 2008-09-18 バイオジェン アイデック エムエイ インコーポレイテッド 治療タンパク質に対する免疫反応を評価するための方法および生成物
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
EP3360900A1 (en) 2006-03-03 2018-08-15 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
SI2573568T1 (sl) * 2007-12-15 2015-05-29 F. Hoffmann-La Roche Ag Razlikovalni test
WO2009091240A1 (en) * 2008-01-15 2009-07-23 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
MX341991B (es) 2010-01-11 2016-09-09 Biogen Ma Inc Ensayo para anticuerpos contra el virus jc.
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
WO2012022774A1 (en) * 2010-08-19 2012-02-23 Roche Diagnostics Gmbh An assay for measurement of antibodies binding to a therapeutic monoclonal antibody
PL3326645T3 (pl) * 2010-10-25 2020-09-21 Biogen Ma Inc. Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM
WO2012175201A1 (en) * 2011-06-20 2012-12-27 Cellzome Ag Methods for the characterization of antibodies
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
CN103439515B (zh) * 2013-08-14 2015-07-15 南方医科大学 一种抗体效价的检测方法
US20170059561A1 (en) * 2015-08-28 2017-03-02 The Florida International University Board Of Trustees Thermally Stable Electrochemical Sensor With Long Shelf-Life
CA3073185A1 (en) * 2017-08-15 2019-02-21 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
CN112730846B (zh) * 2020-12-18 2023-12-15 安渡生物医药(杭州)有限公司 一种用于小鼠血样检测免疫复合物的方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639350A (en) 1970-04-15 1972-02-01 Allied Chem Esterification of terephthalic acid with an alkylene glycol in the presence of guanidine or an alkyl guanidine
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4425112A (en) 1976-02-25 1984-01-10 The United States Of America As Represented By The Department Of Health And Human Services Flow-through centrifuge
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ES2050704T5 (es) 1987-04-27 2004-04-16 Inverness Medical Switzerland Gmbh Inmunoensayos y dispositivos para su realizacion.
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
EP0566695B1 (en) 1991-01-11 1999-06-02 Quidel Corporation A one-step lateral flow assay and nonbibulous support used therein
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH07503543A (ja) 1992-02-04 1995-04-13 クイデル　コーポレイション 乾燥試薬を用いる細菌抗原の簡易化抽出法
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
ES2151902T3 (es) 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
CA2155303C (en) 1993-02-09 2010-04-20 Linda C. Burkly Treatment for insulin dependent diabetes
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6319676B1 (en) 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
JPH11190734A (ja) * 1997-12-26 1999-07-13 Wakamoto Pharmaceut Co Ltd クローン病の検査方法および検査用キット
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
DK1232392T3 (da) 1999-10-12 2003-07-28 Connex Ges Zur Optimierung Von Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring
US6612032B1 (en) 2000-01-31 2003-09-02 Lexmark International, Inc. Manufacturing method for ink jet pen
CA2405448A1 (en) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Method of examining cancer by assaying autoantibody against mdm2 and reagent therefor
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7018847B2 (en) 2000-05-05 2006-03-28 Pharmacia Diagnostics Ab Assay device with timer function
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
JP2002071694A (ja) * 2000-08-25 2002-03-12 Wakamoto Pharmaceut Co Ltd 炎症性腸疾患の検査方法及び検査用キット
DK1340086T3 (da) 2000-10-17 2008-12-01 Besst Test Aps Assay til direkte detektion af en RS-virusrelateret biologisk celle i en legemsvæskepröve
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
US7291477B2 (en) 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
US20030040027A1 (en) * 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
JP4264348B2 (ja) 2001-08-20 2009-05-13 プロテオム システムズ リミテッド 診断検査方法および装置
NZ579583A (en) 2002-02-25 2011-04-29 Elan Pharm Inc Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
CA2498407A1 (en) * 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2004043237A2 (en) * 2002-11-08 2004-05-27 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
AU2004264601A1 (en) * 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti CD20 antibodies and uses therefor
US7238538B2 (en) 2003-09-19 2007-07-03 Freitag Helmut E Chromatographic assay device and methods
JP4933258B2 (ja) 2003-09-22 2012-05-16 クイデル コーポレーション 試料中の複数分析物の検出装置
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
EP1863940B1 (en) 2005-03-03 2012-06-06 Seedlings Life Science Ventures, LLC. Method of risk management for patients undergoing natalizumab treatment
JP2008537595A (ja) * 2005-04-04 2008-09-18 バイオジェン アイデック エムエイ インコーポレイテッド 治療タンパク質に対する免疫反応を評価するための方法および生成物
US20060246513A1 (en) 2005-05-02 2006-11-02 Bohannon Robert C Method and device to detect the presence of analytes in a sample
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
EP2007392A4 (en) 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
EP3360900A1 (en) 2006-03-03 2018-08-15 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
JP3157356U (ja) 2006-07-26 2010-02-18 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 生物学的試料用の分析装置
US7704702B2 (en) 2006-08-10 2010-04-27 Inverness Medical Switzerland Gmbh Test strip for lateral flow assays
WO2008061243A2 (en) 2006-11-16 2008-05-22 Novavax, Inc. Respiratory syncytial virus-virus like particle (vlps)
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
US8871499B2 (en) 2007-08-30 2014-10-28 President And Fellows Of Harvard College Multi-well culture plate comprising gels with different shear modulus
MX341991B (es) 2010-01-11 2016-09-09 Biogen Ma Inc Ensayo para anticuerpos contra el virus jc.

Also Published As

Publication number Publication date
JP6044904B2 (ja) 2016-12-14
US10705095B2 (en) 2020-07-07
IL186431A0 (en) 2008-01-20
WO2006107962A8 (en) 2008-01-24
US8871449B2 (en) 2014-10-28
EP1872136B2 (en) 2022-11-16
HUE052412T2 (hu) 2021-04-28
US20090176256A1 (en) 2009-07-09
LT2645106T (lt) 2017-09-11
CN101351710B (zh) 2013-06-05
DK3264094T3 (da) 2020-11-23
US8124350B2 (en) 2012-02-28
EP2645106A2 (en) 2013-10-02
PT2645106T (pt) 2017-09-18
NZ562784A (en) 2010-07-30
US20150071917A1 (en) 2015-03-12
HK1245884A1 (zh) 2018-08-31
WO2006107962A2 (en) 2006-10-12
PL2645106T3 (pl) 2017-11-30
EP2645106B1 (en) 2017-06-14
EP2645106A3 (en) 2013-10-09
AU2006231511B2 (en) 2012-02-16
JP2014197032A (ja) 2014-10-16
EP1872136A2 (en) 2008-01-02
WO2006107962A9 (en) 2007-04-19
HRP20201840T1 (hr) 2021-04-02
CA2603481A1 (en) 2006-10-12
SI3264094T1 (sl) 2021-04-30
US20180088127A1 (en) 2018-03-29
CY1119412T1 (el) 2018-03-07
EP1872136B9 (en) 2023-02-08
US20120195884A1 (en) 2012-08-02
WO2006107962A3 (en) 2007-03-08
PL3264094T3 (pl) 2021-04-19
RS61229B1 (sr) 2021-01-29
ES2833948T3 (es) 2021-06-16
IL186431A (en) 2012-03-29
EP3264094B1 (en) 2020-08-19
US9709575B2 (en) 2017-07-18
US20210025900A1 (en) 2021-01-28
RS56418B1 (sr) 2018-01-31
JP2008537595A (ja) 2008-09-18
HRP20171310T1 (hr) 2017-12-15
EP3796003A1 (en) 2021-03-24
HUE034318T2 (en) 2018-02-28
ES2640295T3 (es) 2017-11-02
ES2536915T3 (es) 2015-05-29
PT3264094T (pt) 2020-11-24
SI2645106T1 (en) 2018-01-31
DK2645106T3 (en) 2017-10-02
CN101351710A (zh) 2009-01-21
LT3264094T (lt) 2021-04-12
US11686734B2 (en) 2023-06-27
CY1123750T1 (el) 2022-03-24
AU2006231511A1 (en) 2006-10-12
ES2536915T5 (es) 2023-03-01
CA3031792A1 (en) 2006-10-12
JP2012008146A (ja) 2012-01-12
EP1872136B1 (en) 2015-02-18
EP3264094A1 (en) 2018-01-03
CA2603481C (en) 2019-03-12

Similar Documents

Publication Publication Date Title
IL186431A0 (en) Methods and products for evaluating an immune response to a therapeutic protein
HK1205434A1 (en) Soy protein product and the preparation method thereof
ZA200702542B (en) Protein system and food products including same
IL198612A0 (en) Human antibodies to human delta like ligand 4
EP1954244A4 (en) METHOD OF FREEZING AND PRODUCTS OBTAINED BY SAID PROCESS
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
ME01370B (me) Produkt fermentiranog proteina
IL195839A0 (en) New protein conjugates and methods for their preparation
EP2007899A4 (en) ANGIOPOIETIN-LIKE PROTEIN 4-FACED ANTIBODIES AND THEIR USE
IL185530A0 (en) Cereal products containing isomaltulose and methods for preparing cereal products using isomaltulose
EP1924627A4 (en) NEW POLYARYLATE AND METHOD FOR THE PRODUCTION THEREOF
EP1999558A4 (en) METHOD FOR IDENTIFYING FATS AND LOW ANIMALS BY CLASSIFICATION
EP1937294A4 (en) GLYCOLIC AND GLYCOSYLATED THERAPEUTIC PROTEINS DERIVED FROM POULTRY
EP1977003A4 (en) DISEASE-RELATED METHODS AND MEDIUM
ZA200708710B (en) Fermented protein product
GB0518777D0 (en) Products and methods
GB2430345B (en) Improvements in or relating to snack products
HK1117848A1 (en) Assay method for human orotate phosphoribosyltransferase protein
GB0601743D0 (en) Process and products for protein expression
GB0419949D0 (en) Diagnostic products and methods
GB0417483D0 (en) Diagnostic products and methods
GB0523242D0 (en) Control of immune responses
GB0523243D0 (en) Control of immune responses
ITBO20050650A1 (it) Articolo confezionato mediante cuciture e metodo per la sua realizzazione
ZA200903163B (en) Human antibodies to human delta like ligand 4